Drug Delivery to the Brain Via the blood–brain Barrier: a Review of the Literature and Some Recent Patent Disclosures

• Pardridge WM . Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today7(1), 5–7 (2002).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . The blood–brain barrier: bottleneck in brain drug development. NeuroRx2(1), 3–14 (2005).
   PubMedGoogle Scholar
• Alavijeh MS , ChishtyM, QaiserMZ, PalmerAM. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx2(4), 554–571 (2005).
   PubMedGoogle Scholar
• Nau R , SörgelF, EiffertH. Penetration of drugs through the blood–cerebrospinal fluid/blood–brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev.23(4), 858–883 (2010).
   PubMed Web of Science ®Google Scholar
• Spector R , JohansonCE. Vectorial ligand transport through mammalian choroid plexus. Pharm. Res.27(10), 2054–2062 (2010).
   PubMed Web of Science ®Google Scholar
• Jogani V , JinturkarK, VyasTK, MisraA. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat. Drug Deliv. Formul.2(1), 25–40 (2008).
   PubMedGoogle Scholar
• Dhuria SV , HansonLR, Frey Ii WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci.99(4), 1654–1673.
   PubMed Web of Science ®Google Scholar
• Salvatore MF , AiY, FischerBet al. Point source concentration of GDNF may explain failure of Phase II clinical trial. Exp. Neurol. 202(2), 497–505 (2006).
   PubMed Web of Science ®Google Scholar
• Jones AR , ShustaEV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm. Res.24(9), 1759–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Potschka H . Targeting the brain – surmounting or bypassing the blood–brain barrier. Handb. Exp. Pharmacol.197, 411–431 (2010).
   PubMedGoogle Scholar
• Gabathuler R . Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases. Neurobiol. Dis.37(1), 48–57 (2010).
   PubMed Web of Science ®Google Scholar
• Wang BY , XiaAX, ChenPP, NiL, LiuFH, LiFZ. Blood–brain barrier transport of drug-loaded nanoparticle: research advances. J. Int. Pharm. Res.37(1), 40–42 (2010).
   Google Scholar
• Ligade PC , JadhavKR, KadamVJ. Brain drug-delivery system: an overview. Curr. Drug Ther.5(2), 105–110 (2010).
   Google Scholar
• Abbott NJ , PatabendigeAAK, DolmanDEM, YusofSR, BegleyDJ. Structure and function of the blood–brain barrier. Neurobiol. Dis.37(1), 13–25 (2010).
   PubMed Web of Science ®Google Scholar
• Pries AR , KueblerWM. Normal endothelium. Handb. Exp. Pharmacol.176(Part 1), 1–40 (2006).
   PubMedGoogle Scholar
• Campbell M , KiangAS, KennaPFet al. RNAi-mediated reversible opening of the blood–brain barrier. J. Gene Med. 10(8), 930–947 (2008).
   PubMed Web of Science ®Google Scholar
• Campbell M , OzakiE, HumphriesP. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opin. Drug Deliv.7(7), 859–869 (2010).
   PubMed Web of Science ®Google Scholar
• Wolburg H , NoellS, MackA, Wolburg-BuchholzK, Fallier-BeckerP. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res.335(1), 75–96 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer H , GottschlichR, SeeligA. Blood–brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol.165(3), 201–211 (1998).
   PubMed Web of Science ®Google Scholar
• Seelig A , GerebtzoffG. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin. Drug Metabol. Toxicol.2(5), 733–752 (2006).
   PubMed Web of Science ®Google Scholar
• Dallas S , MillerDS, BendayanR. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev.58(2), 140–161 (2006).
   PubMed Web of Science ®Google Scholar
• Miller DS . Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends Pharmacol. Sci.31, 246–254 (2010).
   PubMed Web of Science ®Google Scholar
• Tsuji A . Small-molecular drug transfer across the blood–brain barrier via carrier-mediated transport systems. NeuroRx2(1), 54–62 (2005).
   PubMedGoogle Scholar
• Ricci M , BlasiP, GiovagnoliS, RossiC. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr. Med. Chem.13(15), 1757–1775 (2006).
   PubMed Web of Science ®Google Scholar
• Giacomini KM , HuangSM, TweedieDJet al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3), 215–236 (2010).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . Biopharmaceutical drug targeting to the brain. J. Drug Target.18(3), 11 (2010).
   Google Scholar
• Mahar Doan KM , HumphreysJE, WebsterLOet al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303(3), 1029–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas FC , TaskarK, RudrarajuVet al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood–brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26(11), 2486–2494 (2009).
   PubMed Web of Science ®Google Scholar
• Schnyder A , HuwylerJ. Drug transport to brain with targeted liposomes. NeuroRx2(1), 99–107 (2005).
   PubMedGoogle Scholar
• Pardridge WM , TrigueroD, BuciakJ, YangJ. Evaluation of cationized rat albumin as a potential blood–brain barrier drug transport vector. J. Pharmacol. Exp. Ther.255(2), 893–899 (1990).
   PubMed Web of Science ®Google Scholar
• Frankel AD , PaboCO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell55(6), 1189–1193 (1988).
   PubMed Web of Science ®Google Scholar
• Schmidt N , MishraA, LaiGH, WongGCL. Arginine-rich cell-penetrating peptides. FEBS Lett.584(9), 1806–1813 (2010).
   PubMed Web of Science ®Google Scholar
• Wender PA , GalliherWC, GounEA, JonesLR, PillowTH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev.60(4–5), 452–472 (2008).
   PubMed Web of Science ®Google Scholar
• Lee HJ , PardridgeWM. Pharmacokinetics and delivery of tat and t1-protein conjugates to tissues in vivo. Bioconjug. Chem.12(6), 995–999 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang T , OlsonES, NguyenQT, RoyM, JenningsPA, TsienRY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA101(51), 17867–17872 (2004).
   PubMed Web of Science ®Google Scholar
• Pham W , ZhaoBQ, LoEH, MedarovaZ, RosenB, MooreA. Crossing the blood–brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging. NeuroImage28(1), 287–292 (2005).
   PubMed Web of Science ®Google Scholar
• Dehouck B , FenartL, DehouckMP, PierceA, TorpierG, CecchelliR. A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier. J. Cell Biol.138(4), 877–889 (1997).
   PubMed Web of Science ®Google Scholar
• Fillebeen C , DescampsL, DehouckMPet al. Receptor-mediated transcytosis of lactoferrin through the blood–brain barrier. J. Biol. Chem. 274(11), 7011–7017 (1999).
   PubMed Web of Science ®Google Scholar
• Demeule M , PoirierJ, JodoinJet al. High transcytosis of melanotransferrin (P97) across the blood–brain barrier. J. Neurochem. 83(4), 924–933 (2002).
   PubMed Web of Science ®Google Scholar
• Demeule M , ReginaA, CheCet al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324(3), 1064–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Abulrob A , ZhangJ, TanhaJ, MacKenzieR, StanimirovicD. Single domain antibodies as blood–brain barrier delivery vectors. Int. Congr. Ser.1277, 212–223 (2005).
   Google Scholar
• Muruganandam A , TanhaJ, NarangS, StanimirovicD. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood–brain barrier endothelium. FASEB J.16(2), 240–242 (2002).
   PubMed Web of Science ®Google Scholar
• Tanha J , MuruganandamA, StanimirovicD. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med.89, 435–449 (2003).
   PubMedGoogle Scholar
• Abulrob A , SprongH, Van Bergen En Henegouwen P, Stanimirovic D. The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem.95(4), 1201–1214 (2005).
   PubMed Web of Science ®Google Scholar
• Rip J , SchenkGJ, De Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv.6(3), 227–237 (2009).
   PubMed Web of Science ®Google Scholar
• Shi N , ZhangY, ZhuC, BoadoRJ, PardridgeWM. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl Acad. Sci. USA98(22), 12754–12759 (2001).
   PubMed Web of Science ®Google Scholar
• Mishra V , MahorS, RawatAet al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14(1), 45–53 (2006).
   PubMed Web of Science ®Google Scholar
• Ulbrich K , HekmataraT, HerbertE, KreuterJ. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur. J. Pharm. Biopharm.71(2), 251–256 (2009).
   PubMed Web of Science ®Google Scholar
• Pardridge WM , BuciakJL, FridenPM. Selective transport of an anti-transferrin receptor antibody through the blood–brain barrier in vivo. J. Pharmacol. Exp. Ther.259(1), 66–70 (1991).
   PubMed Web of Science ®Google Scholar
• Huwyler J , WuD, PardridgeWM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA93, 14164–14169 (1996).
   PubMed Web of Science ®Google Scholar
• Gosk S , VermehrenC, StormG, MoosT. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab.24(11), 1193–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Y , PardridgeWM. Near complete rescue of experimental Parkinson‘s disease with intravenous, nonviral GDNF gene therapy. Pharm. Res.26(5), 1059–1063 (2009).
   PubMed Web of Science ®Google Scholar
• Boado RJ , ZhouQH, LuJZ, HuiEKW, PardridgeWM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm.7(1), 237–244 (2010).
   PubMed Web of Science ®Google Scholar
• Pardridge WM , KangYS, BuciakJL, YangJ. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate. Pharm. Res.12(6), 807–816 (1995).
   PubMed Web of Science ®Google Scholar
• Boado RJ , ZhangY, PardridgeWM. Humanization of antihuman insulin receptor antibody for drug targeting across the human blood–brain barrier. Biotechnol. Bioeng.96(2), 381–391 (2007).
   PubMed Web of Science ®Google Scholar
• Boado RJ , HuiEKW, LuJZ, ZhouQH, PardridgeWM. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol.146(1–2), 84–91 (2010).
   PubMed Web of Science ®Google Scholar
• Davis B , MorrisT. Physiological parameters in laboratory animals and humans. Pharm. Res.10(7), 1093–1095 (1993).
   PubMed Web of Science ®Google Scholar
• Boado RJ , PardridgeWM. Comparison of blood–brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG–GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos.37(12), 2299–2304 (2009).
   PubMed Web of Science ®Google Scholar
• Pardridge WM , BoadoRJ. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody–GDNF fusion protein for targeted blood–brain barrier delivery. Pharm. Res.26(10), 2227–2236 (2009).
   PubMed Web of Science ®Google Scholar
• Boado RJ , ZhangY, XiaCF, PardridgeWM. Fusion antibody for Alzheimer‘s disease with bidirectional transport across the blood–brain barrier and Aβ fibril disaggregation. Bioconjug. Chem.18(2), 447–455 (2007).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev.59(2–3), 141–152 (2007).
   PubMed Web of Science ®Google Scholar
• Pardridge WM . Tyrosine hydroxylase replacement in experimental Parkinson‘s disease with transvascular gene therapy. NeuroRx2(1), 129–138 (2005).
   PubMedGoogle Scholar
• Ulbrich K , KnoblochT, KreuterJ. Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). J. Drug Target.19(2), 125–132 (2011).
   PubMed Web of Science ®Google Scholar
• Golden PL , MaccagnanTJ, PardridgeWM. Human blood–brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest.99(1), 14–18 (1997).
   PubMed Web of Science ®Google Scholar
• Couce ME , GreenD, BrunettoA, LloydRV, BurgueraB. Limited brain access for leptin in obesity. Pituitary4(1–2), 101–110 (2001).
   PubMedGoogle Scholar
• Kurrimbux D , GaffenZ, FarrellCL, MartinD, ThomasSA. The involvement of the blood–brain and the blood–cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience123(2), 527–536 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett GL , TrieuJ, NaimT. The identification of leptin-derived peptides that are taken up by the brain. Regul. Pept.155(1–3), 55–61 (2009).
   PubMedGoogle Scholar
• Liu Y , LiJ, ShaoKet al. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31(19), 5246–5257 (2010).
   PubMed Web of Science ®Google Scholar
• Banks WA , CleverCM, FarrellCL. Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am. J. Physiol. Endocrinol. Metab.278(6), E1158–E1165 (2000).
   PubMed Web of Science ®Google Scholar
• Nykjaer A , WillnowTE. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol.12(6), 273–280 (2002).
   PubMed Web of Science ®Google Scholar
• May P , WoldtE, MatzRL, BoucherP. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann. Med.39(3), 219–228 (2007).
   PubMed Web of Science ®Google Scholar
• Yepes M , SandkvistM, MooreEG, BuggeTH, StricklandDK, LawrenceDA. Tissue-type plasminogen activator induces opening of the blood–brain barrier via the LDL receptor-related protein. J. Clin. Invest.112(10), 1533–1540 (2003).
   PubMed Web of Science ®Google Scholar
• Lillis AP , Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev.88(3), 887–918 (2008).
   PubMed Web of Science ®Google Scholar
• Gosselet F , CandelaP, SevinE, BerezowskiV, CecchelliR, FenartL. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood–brain barrier: use of an in vitro model. Brain Res.1249(C), 34–42 (2009).
   PubMed Web of Science ®Google Scholar
• Candela P , GosseletF, MillerFet al. Physiological pathway for low-density lipoproteins across the blood–brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 15(5–6), 254–264 (2008).
   PubMed Web of Science ®Google Scholar
• Tucker IG , FlorenceAT. Interactions of ionic and nonionic surfactants with plasma low density lipoprotein. J. Pharm. Pharmacol.35(11), 705–711 (1983).
   PubMed Web of Science ®Google Scholar
• Lacko AG , NairM, ProkaiL, McConarthyWJ. Prospects and challenges of the development of lipoprotein-based formulations for anticancer drugs. Expert Opin. Drug Deliv.4(6), 665–675 (2007).
   PubMed Web of Science ®Google Scholar
• Nikanjam M , BlakelyEA, BjornstadKA, ShuX, BudingerTF, ForteTM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm.328(1), 86–94 (2007).
   PubMedGoogle Scholar
• Nikanjam M , GibbsAR, HuntCA, BudingerTF, ForteTM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release124(3), 163–171 (2007).
   PubMed Web of Science ®Google Scholar
• Kreuter J , AlyautdinRN, KharkevichDA, IvanovAA. Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res.674(1), 171–174 (1995).
   PubMed Web of Science ®Google Scholar
• Kreuter J . Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev.47(1), 65–81 (2001).
   PubMed Web of Science ®Google Scholar
• Kreuter J , ShamenkovD, PetrovVet al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J. Drug Target. 10(4), 317–325 (2002).
   PubMed Web of Science ®Google Scholar
• Olivier J -C. Drug transport to brain with targeted nanoparticles. NeuroRx2, 108–119 (2005).
   PubMedGoogle Scholar
• Kim HR , AndrieuxK, GilSet al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins on receptor-mediated endocytosis. Biomacromolecules 8(3), 793–799 (2007).
   PubMed Web of Science ®Google Scholar
• Kim HR , GilS, AndrieuxKet al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol. Life Sci. 64(3), 356–364 (2007).
   PubMed Web of Science ®Google Scholar
• Gelperina S , MaksimenkoO, KhalanskyAet al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 74(2), 157–163 (2010).
   PubMed Web of Science ®Google Scholar
• Zensi A , BegleyD, PontikisCet al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137(1), 78–86 (2009).
   PubMed Web of Science ®Google Scholar
• Zensi A , BegleyD, PontikisCet al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood–brain barrier and enter the rodent brain. J. Drug Target. 18(10), 842–848 (2010).
   PubMed Web of Science ®Google Scholar
• Spencer BJ , VermaIM. Targeted delivery of proteins across the blood–brain barrier. Proc. Natl Acad. Sci. USA104(18), 7594–7599 (2007).
   PubMed Web of Science ®Google Scholar
• Pan W , KastinAB, ZankelTC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood–brain barrier. J. Cell Sci.117(21), 5071–5078 (2004).
   PubMed Web of Science ®Google Scholar
• Gabathuler R , ArthurG, KennardMet al. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood–brain barrier. Int. Congr. Ser. 1277, 171–184 (2005).
   Google Scholar
• Karkan D , PfeiferC, VitalisTZet al. A unique carrier for delivery of therapeutic compounds beyond the blood–brain barrier. PLoS ONE 3(6), e2469 (2008).
   PubMed Web of Science ®Google Scholar
• Huang R , KeW, HanLet al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J. Cereb. Blood Flow Metab. 29(12), 1914–1923 (2009).
   PubMed Web of Science ®Google Scholar
• Huang R , KeW, HanLet al. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res. Bull. 81(6), 600–604 (2010).
   PubMed Web of Science ®Google Scholar
• Huang R , KeW, LiuYet al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci. 290(1–2), 123–130 (2010).
   PubMed Web of Science ®Google Scholar
• Demeule M , CurrieJC, BertrandYet al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain-delivery vector Angiopep-2. J. Neurochem. 106(4), 1534–1544 (2008).
   PubMed Web of Science ®Google Scholar
• Regina A , DemeuleM, CheCet al. Anti-tumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155(2), 185–197 (2008).
   PubMed Web of Science ®Google Scholar
• Gabathuler R . Development of new peptide vectors for the transport of therapeutic across the blood–brain barrier. Ther. Deliv.1(4), 571–586 (2010).
   PubMedGoogle Scholar
• Che C , YangG, ThiotCet al. New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53(7), 2814–2824 (2010).
   PubMed Web of Science ®Google Scholar
• Ke W , ShaoK, HuangRet al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30(36), 6976–6985 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar P , WuH, McBrideJLet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Lafon M . Rabies virus receptors. J. Neurovirol.11(1), 82–87 (2005).
   PubMed Web of Science ®Google Scholar
• Wessler I , KirkpatrickCJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol.154(8), 1558–1571 (2008).
   PubMed Web of Science ®Google Scholar
• Gotti C , ClementiF. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol.74(6), 363–396 (2004).
   PubMed Web of Science ®Google Scholar
• Abbruscato TJ , LopezSP, MarkKS, HawkinsBT, DavisTP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci.91(12), 2525–2538 (2002).
   PubMed Web of Science ®Google Scholar
• Pulford B , ReimN, BellAet al. Liposome-siRNA-peptide complexes cross the blood–brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures. PLoS ONE 5(6), 1–13 (2010).
   Web of Science ®Google Scholar
• Liu Y , HuangR, HanLet al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30(25), 4195–4202 (2009).
   PubMed Web of Science ®Google Scholar
• Wilkins ME , LiX, SmartTG. Tracking cell surface GABAB receptors using an α-bungarotoxin tag. J. Biol. Chem.283(50), 34745–34752 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Y , LiuGQ. Sodium and chloride-dependent high and low-affinity uptakes of GABA by brain capillary endothelial cells. Brain Res.808(1), 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• Chen W , ZhanC, GuBet al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J. Drug Target. DOI: 10.3109/1061186X.1062010.1492523 (2010) (Epub ahead of print).
   Google Scholar
• Xiang L , ZhouR, FuA, XuX, HuangY, HuC. Targeted delivery of large fusion protein into hippocampal neurons by systemic administration. J. Drug Target. DOI: 10.3109/1061186X.1062010.1523788 (2010) (Epub ahead of print).
   Google Scholar
• Gaillard PJ , BrinkA, de Boer AG. Diphtheria toxin receptor-targeted brain drug delivery. Int. Congr. Ser.1277, 185–198 (2005).
   Google Scholar
• Gaillard PJ , de Boer AG. A novel opportunity for targeted drug delivery to the brain. J. Control. Release116(2), e60–e62 (2006).
   PubMed Web of Science ®Google Scholar
• Anonymous. To-BBB: leverages new platform to target brain tumours, form partnerships. Neurotech Insights.6(8), 19 (2010).
   Google Scholar

Patents

• Muruganandam A, Tanha J, Narang S, Stanimirovic D. US0162422 (2009).
   Google Scholar
• National Research Council of Canada. WO036021 (2007).
   Google Scholar
• Abulrob A, Stanimirovic D, Muruganandam A. US0047300 (2009).
   Google Scholar
• Wisconsin Alumni Research Foundation. WO07143711 (2007).
   Google Scholar
• Wisconsin Alumni Research Foundation. US07744879 (2010).
   Google Scholar
• Armagen Technologies, Inc. WO044323 (2007).
   Google Scholar
• Armagen Technologies, Inc. WO108048 (2010).
   Google Scholar
• Armagen Technologies, Inc. WO022349 (2008).
   Google Scholar
• Pardridge WM, Boado RJ. US07741446 (2010).
   Google Scholar
• The Regents of The University of California. WO9822092 (1998).
   Google Scholar
• Medtronic, Inc. WO033253 (2008).
   Google Scholar
• Angiochem, Inc. WO063123 (2010).
   Google Scholar
• The Regents of The University of California. WO145659 (2007).
   Google Scholar
• Blanchette Rockefeller Neurosciences Institute. US7682627 (2010).
   Google Scholar
• Nelson T, Quattrone A, Alkon D. US7514402 (2009).
   Google Scholar
• Blanchette Rockefeller Neurosciences Institute. US7576055 (2009).
   Google Scholar
• Kreuter J, Alyautdin RN, Karkevich DA, Sabel BA. US6117454 (2000).
   Google Scholar
• LTS Lohmann Therapie-Systeme AG. WO110152 (2007).
   Google Scholar
• Kreuter J, Langer K, Weber C, Alyautdin RN. US0131692 (2004).
   Google Scholar
• LTS Lohmann Therapie-Systeme AG. WO095652 (2008).
   Google Scholar
• The Salk Institute for Biological Studies. US0015117 (2010).
   Google Scholar
• Angiochem, Inc.: WO086870 (2006).
   Google Scholar
• Angiochem, Inc. WO009229 (2007).
   Google Scholar
• Angiochem, Inc. WO079790 (2009).
   Google Scholar
• Angiochem, Inc. EP2164866 (2010).
   Google Scholar
• Immune Disease Institute, Inc. WO054544 (2008).
   Google Scholar
• To-BBB Holding BV. WO118013 (2008).
   Google Scholar
• To-BBB Holding BV. WO095940 (2010).
   Google Scholar

Websites

• ArmaGen® Technologies. www.armagen.com
   Google Scholar
• Raptor Pharmaceutical Corp. www.raptorpharma.com
   Google Scholar
• biOasis Technologies Inc. www.bioasis.ca
   Google Scholar
• Angiochem Inc. www.angiochem.com
   Google Scholar
• To-BBB Technologies. www.tobbb.com
   Google Scholar